Literature DB >> 8080676

Primary chemotherapy and delayed surgery for non-metastatic telangiectatic osteosarcoma of the extremities. Results in 28 patients.

G Bacci1, P Picci, S Ferrari, L Sangiorgi, A Zanone, A Brach del Prever.   

Abstract

28 patients with telangiectatic osteogenic sarcoma of the extremities were treated between March 1983 and March 1990 with neoadjuvant chemotherapy according to two different protocols activated successively. With the first protocol, patients preoperatively received high dose methotrexate (HDMTX)-cisplatinum (CDP) and postoperatively, depending on the histological response, either HDMTX-CDP-doxorubicin (ADM) or ADM-"BCD". With the second protocol patients were preoperatively treated with HDMTX-CDP-ADM and postoperatively either with the same drugs or with the same drugs plus ifosfamide and VP-16. Preoperatively, CDP was delivered intraarterially. A good histological response (tumour necrosis > 90%) was observed in 25 patients (89%) and at a mean follow-up of 5 years (2-9 years) 23 patients (82%) remained continuously disease-free and 5 developed lung metastases. These results are better than those obtained in 272 contemporary cases of conventional osteosarcoma of the extremities treated with the same protocols (62% good histological responses and 61% continuously disease-free survival).

Entities:  

Mesh:

Year:  1994        PMID: 8080676     DOI: 10.1016/0959-8049(94)90532-0

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  5 in total

1.  Telangiectatic osteosarcoma: a review of 87 cases.

Authors:  Andrea Angelini; Andreas F Mavrogenis; Giulia Trovarelli; Stefano Ferrari; Piero Picci; Pietro Ruggieri
Journal:  J Cancer Res Clin Oncol       Date:  2016-07-28       Impact factor: 4.553

2.  Telangiectatic osteosarcoma: a review of literature.

Authors:  Jun-Jian Liu; Shen Liu; Jian-Guang Wang; Wei Zhu; Ying-Qi Hua; Wei Sun; Zheng-Dong Cai
Journal:  Onco Targets Ther       Date:  2013-05-28       Impact factor: 4.147

3.  Preoperative easily misdiagnosed telangiectatic osteosarcoma: clinical-radiologic-pathologic correlations.

Authors:  Zhen-Hua Gao; Jun-Qiang Yin; Da-Wei Liu; Quan-Fei Meng; Jia-Ping Li
Journal:  Cancer Imaging       Date:  2013-12-11       Impact factor: 3.909

4.  Characteristics and prognosis of telangiectatic osteosarcoma: a population-based study using the Surveillance, Epidemiology and End Results (SEER) database.

Authors:  Mingfang Xu; Nan Dai; Xueqin Yang; Wei Guan; Yu Pu; Dong Wang; Liangjun Yin; Mao Nie
Journal:  Ann Transl Med       Date:  2021-05

5.  Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort.

Authors:  Sigbjørn Smeland; Stefan S Bielack; Jeremy Whelan; Mark Bernstein; Pancras Hogendoorn; Mark D Krailo; Richard Gorlick; Katherine A Janeway; Fiona C Ingleby; Jakob Anninga; Imre Antal; Carola Arndt; Ken L B Brown; Trude Butterfass-Bahloul; Gabriele Calaminus; Michael Capra; Catharina Dhooge; Mikael Eriksson; Adrienne M Flanagan; Godehard Friedel; Mark C Gebhardt; Hans Gelderblom; Robert Goldsby; Holcombe E Grier; Robert Grimer; Douglas S Hawkins; Stefanie Hecker-Nolting; Kirsten Sundby Hall; Michael S Isakoff; Gordana Jovic; Thomas Kühne; Leo Kager; Thekla von Kalle; Edita Kabickova; Susanna Lang; Ching C Lau; Patrick J Leavey; Stephen L Lessnick; Leo Mascarenhas; Regine Mayer-Steinacker; Paul A Meyers; Raj Nagarajan; R Lor Randall; Peter Reichardt; Marleen Renard; Catherine Rechnitzer; Cindy L Schwartz; Sandra Strauss; Lisa Teot; Beate Timmermann; Matthew R Sydes; Neyssa Marina
Journal:  Eur J Cancer       Date:  2019-01-25       Impact factor: 9.162

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.